Search
Ketotifen
go.drugbank.com/drugs/DB00920ApprovedInvestigational[L32283] In addition, oral ketotifen is used in Mexico and across Europe for the treatment of various allergic symptoms and disorders,[A231204] including urticaria, mastocytosis, and food allergy. … It has a similar structure to some other first-generation antihistamines such as [cyproheptadine] and [azatadine].
Products: CHETOTIFENE MYLAN GENERICSFentanyl
go.drugbank.com/drugs/DB00813ApprovedIllicitInvestigationalVet approvedFentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. … [L6751] Fentanyl was FDA approved in 1968.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613]
Products: DUROGESIC D-TRANS, CITRATO DE FENTANILO 0.05MG/MLLasofoxifene
go.drugbank.com/drugs/DB06202ApprovedInvestigationalWithdrawnIt gained approval by European Commission in March 2009. … Later Fablyn was developed as a result of a research collaboration between Pfizer and Ligand Pharmaceuticals with a newly submitted New Drug Application in 2008.
Olipudase alfa
go.drugbank.com/drugs/DB12835ApprovedInvestigational[A251590] Olipudase alfa gained its first global approval in Japan on March 28, 2022. … [A251590] It was later approved by the European Commission on June 28, 2022 [L42740] and by the FDA on August 31, 2022.[L43145]
Paroxysmal Nocturnal Hemoglobinuria (PNH)
go.drugbank.com/conditions/DBCOND0028737Synonyms: (Haemoglobinuria: [March]) or (Marchiafava-Micheli syndrome)Elranatamab
go.drugbank.com/drugs/DB15395ApprovedInvestigationalElranatamab is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager. … [L47820] Elranatamab was also approved by the European Commission on December 8, 2023.[L50437]
Talquetamab
go.drugbank.com/drugs/DB16678ApprovedInvestigationalTalquetamab is a IgG4-PAA bispecific G protein-coupled receptor class C group 5 member D (GPRC5D)-directed CD3 T-cell engager. … [L48822] On August 9, 2023, talquetamab was granted FDA accelerated approval.[L47770]
Synonyms: IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONAL, IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONALDavesomeran
go.drugbank.com/drugs/DB17091ApprovedInvestigationalModerna Bivalent vaccine elicit a higher seroresponse both against the original SARS-CoV-2 strain and the BA.4/5 strain compared to that of the Moderna COVID-19 Vaccine. … [L43882] A phase 2 and 3 open-label study in participants 18 years or older who had previously received a two-dose primary series and one booster dose of Moderna COVID-19 Vaccine demonstrated that the
Mixtures: Spikevax Bivalent (original / Omicron Ba.4/5)Selpercatinib
go.drugbank.com/drugs/DB15685ApprovedInvestigational[L13604] Selpercatinib is also approved by the European Commission. … Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.
Synonyms: 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrileALTU-135
go.drugbank.com/drugs/DB05330InvestigationalALTU-135 has been granted orphan drug and fast-track designation as well as CMA Pilot 2 program status by the Food and Drug Administration (FDA).